Vulvodynia: What We Know and Where We Should Be Going

Logan M. Havemann, David R. Cool, Pascal Gagneux, Michael P. Markey, Jerome L. Yaklic, Rose A. Maxwell, Ashvin Iyer, Steven R. Lindheim

Research output: Contribution to journalArticle

Abstract

Objective The aim of the study was to review the current nomenclature and literature examining microbiome cytokine, genomic, proteomic, and glycomic molecular biomarkers in identifying markers related to the understanding of the pathophysiology and diagnosis of vulvodynia (VVD). Materials and Methods Computerized searches of MEDLINE and PubMed were conducted focused on terminology, classification, and "omics" variations of VVD. Specific MESH terms used were VVD, vestibulodynia, metagenomics, vaginal fungi, cytokines, gene, protein, inflammation, glycomic, proteomic, secretomic, and genomic from 2001 to 2016. Using combined VVD and vestibulodynia MESH terms, 7 references were identified related to vaginal fungi, 15 to cytokines, 18 to gene, 43 to protein, 38 to inflammation, and 2 to genomic. References from identified publications were manually searched and cross-referenced to identify additional relevant articles. A narrative synthesis of the articles was conducted; however, meta-analysis was not conducted because of substantial heterogeneity in the studies and limited numbers of control-matched studies. Results Varying definitions of VVD complicate a meta-analysis, and standard definitions will better allow for comparisons of studies and enhance the applicability of evidence to patient populations. Although data are still limited, genomic and molecular diagnostic testings continue to be investigated as potential tools for the diagnosis of VVD. Conclusions Standardized nomenclature will allow for comparability of studies and progress in research related to the pathophysiology of VVD and to facilitate clinical decision making and treatment choices. Although the current understanding of the pathogenesis of VVD is limited, there are new opportunities to explore potential diagnostic markers differences in women with VVD, which may lead to targeted therapy.

Original languageEnglish (US)
Pages (from-to)150-156
Number of pages7
JournalJournal of Lower Genital Tract Disease
Volume21
Issue number2
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Keywords

  • genomics
  • glycomics
  • microbiome
  • proteomics
  • vulvodynia

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Vulvodynia: What We Know and Where We Should Be Going'. Together they form a unique fingerprint.

  • Cite this

    Havemann, L. M., Cool, D. R., Gagneux, P., Markey, M. P., Yaklic, J. L., Maxwell, R. A., Iyer, A., & Lindheim, S. R. (2017). Vulvodynia: What We Know and Where We Should Be Going. Journal of Lower Genital Tract Disease, 21(2), 150-156. https://doi.org/10.1097/LGT.0000000000000289